The clinical leads for the neurology workstream were appointed on 18th July 2017 and endorsed by the Association of British Neurologists. Tim Gustafson (email@example.com) is the project manager for this workstream. You can read more about the appointment of clinical leads here.
The GIRFT neurology methodology document, available here, describes the methodology used for the regional presentations and the way services are provided to patients with neurological disorders across England. It also highlights some of the key findings from regional analysis. These findings have been the basis for the GIRFT regional presentations and will provide the context for the analysis presented at GIRFT trust provider visits. Click here to download the accompanying excel spreadsheet, which provides some background information on which the methodology is based.
Clinical Lead: Dr Geraint Fuller
Consultant Neurologist, Gloucestershire Hospitals NHS Foundation Trust (Gloucester Royal Hospital).
Dr Fuller has worked as a Consultant Neurologist in Gloucester since 1994. He has an interest in general neurology and neurological education. He has been Chair of the Specialty Advisory Committee for Neurology that oversees neurological training in the UK, and was President of the Association of British Neurologists from 2013 to 2015.
“Neurology is a specialty that is changing dramatically and can now provide increasingly effective treatment for many patients with neurological disease. Access to these
treatments across the UK is patchy. The GIRFT project provides an opportunity to improve this so that all patients with neurological disease can receive the most effective and appropriate treatments.”
Senior Clinical Advisor: Professor Adrian Williams
Professor of Neurology, University Hospitals Birmingham NHS Foundation Trust, and NHSE Chair of the Neurosciences CRG, the National Neurosciences Advisory Group and the West Midlands Senate.
“I am delighted to become part of the formidable GIRFT team and look forward to applying its successful techniques to some of the longstanding but solvable problems of timely and equitable access of patients to neurological interventions of value.”